ERBB2 and lung cancer: Even though HER2 amplifications (2–3%) or overexpression (2.5%) occur to a lesser extent in lung cancer, trastuzumab deruxtecan, an antibody–drug conjugate, received accelerated approval by FDA for patients with HER2-mutant non-small-cell lung cancer in August 2022 due to an encouraging phase 2 study [36].